RxDoctor Payments Data

Karl Valrey, MD

Internal Medicine · Olivehurst, CANPI 1356325120

Payments from drug & device makers

$632in general payments, 2019–2025

Across 35 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$204
  • Johnson & Johnson$100
  • Hologic Sales And Service, LLC$79
  • Sanofi Pasteur Inc.$46
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$27
  • Novo Nordisk$20
  • plus $156 from 10 others

What the payments were for

  • Food & beverage$632100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$632 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$537
Medicare patients
74
Services billed
213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$102,499
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$79,016
JanuviaSitagliptin Phosphate100$77,686
JardianceEmpagliflozin57$50,229
XareltoRivaroxaban18$25,560
OzempicSemaglutide23$21,341
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog45$21,258
EntrestoSacubitril/Valsartan11$14,929
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen621$14,836
Tresiba Flextouch U-100Insulin Degludec19$11,389
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$10,907
MultaqDronedarone Hcl11$8,890
Breo ElliptaFluticasone/Vilanterol13$8,751
Albuterol Sulfate HfaAlbuterol Sulfate199$8,390
Varenicline Tartrate26$4,647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$102,49990 claims
GSKTrelegy Ellipta, Breo Ellipta$18$87,76783 claims
MerckJanuvia$18$77,686100 claims
Boehringer IngelheimJardiance$12$50,22957 claims
Johnson & JohnsonXarelto$100$25,56018 claims
Novo NordiskOzempic$20$21,34123 claims
NovartisEntresto$12$14,92911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Olivehurst

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →